A 
Astellas Pharma 4503.T · JPY
Health Care · Pharmaceuticals · Tokyo Stock Exchange · 🇯🇵 Japan
2,582.5
+4.49%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in JPY, from our data supplier.
Revenue
¥2.14trn
FY2017FY2026
Net income
¥291.54bn
FY2017FY2026
Free cash flow
¥508.53bn
FY2017FY2026
Shareholders' equity
¥1.83trn
FY2017FY2026
Income statement
Fiscal years
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ¥2.14trn | ¥1.91trn | ¥1.60trn | ¥1.52trn | ¥1.30trn | ¥1.25trn | ¥1.30trn | ¥1.31trn | ¥1.30trn | ¥1.31trn |
| Gross profit | ¥1.59trn | ¥1.56trn | ¥1.31trn | ¥1.23trn | ¥1.04trn | ¥1.00trn | ¥1.02trn | ¥1.01trn | ¥1.01trn | ¥991.16bn |
| Research and development | ¥314.83bn | ¥327.70bn | ¥294.20bn | ¥276.10bn | ¥246.00bn | ¥224.50bn | ¥224.20bn | ¥208.70bn | ¥220.80bn | ¥208.10bn |
| Operating income | ¥419.70bn | ¥263.54bn | ¥124.61bn | ¥285.43bn | ¥220.02bn | ¥250.90bn | ¥279.42bn | ¥280.14bn | ¥271.12bn | ¥276.42bn |
| Net income | ¥291.54bn | ¥50.75bn | ¥17.05bn | ¥98.71bn | ¥124.09bn | ¥120.59bn | ¥195.41bn | ¥222.26bn | ¥164.68bn | ¥218.70bn |
| Diluted earnings per share | 162.31 | 28.23 | 9.52 | 54.83 | 68.05 | 65.05 | 105.14 | 118.47 | 85.65 | 108.35 |
Balance sheet
At each fiscal year end
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | ¥3.57trn | ¥3.34trn | ¥3.57trn | ¥2.46trn | ¥2.33trn | ¥2.27trn | ¥2.32trn | ¥1.90trn | ¥1.86trn | ¥1.81trn |
| Cash and short-term investments | ¥281.61bn | ¥188.37bn | ¥335.69bn | ¥376.84bn | ¥315.99bn | ¥326.13bn | ¥327.85bn | ¥313.68bn | ¥331.73bn | ¥340.92bn |
| Total liabilities | ¥1.74trn | ¥1.83trn | ¥1.97trn | ¥948.56bn | ¥872.09bn | ¥887.51bn | ¥1.03trn | ¥639.25bn | ¥589.92bn | ¥542.26bn |
| Debt | — | ¥937.09bn | ¥1.01trn | ¥200.01bn | ¥212.74bn | ¥278.26bn | ¥473.38bn | ¥53.31bn | ¥49.87bn | ¥28.89bn |
| Shareholders' equity | ¥1.83trn | ¥1.51trn | ¥1.60trn | ¥1.51trn | ¥1.46trn | ¥1.39trn | ¥1.29trn | ¥1.26trn | ¥1.27trn | ¥1.27trn |
| Shares outstanding | 1,796m | 1,797m | 1,790m | 1,800m | 1,823m | 1,854m | 1,859m | 1,876m | 1,923m | 2,019m |
Cash flow
Fiscal years
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | ¥566.25bn | ¥201.61bn | ¥181.32bn | ¥327.77bn | ¥257.44bn | ¥306.84bn | ¥222.00bn | ¥261.43bn | ¥314.46bn | ¥237.23bn |
| Capital spending | −¥57.72bn | −¥37.00bn | −¥38.06bn | −¥88.54bn | −¥76.45bn | −¥77.44bn | −¥77.89bn | −¥25.19bn | −¥25.08bn | −¥29.01bn |
| Free cash flow | ¥508.53bn | ¥164.61bn | ¥143.27bn | ¥239.23bn | ¥181.00bn | ¥229.40bn | ¥144.11bn | ¥236.24bn | ¥289.39bn | ¥208.22bn |
| Dividends paid | −¥136.10bn | −¥128.99bn | −¥116.65bn | −¥100.36bn | −¥85.24bn | −¥76.16bn | −¥73.54bn | −¥72.07bn | −¥71.63bn | −¥70.12bn |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ¥640.91bn | ¥537.92bn | ¥571.21bn | ¥524.32bn | ¥505.79bn | ¥459.29bn | ¥517.41bn | ¥462.50bn |
| Gross profit | ¥482.54bn | ¥408.49bn | ¥422.08bn | ¥386.07bn | ¥410.96bn | ¥382.44bn | ¥418.88bn | ¥379.81bn |
| Operating income | ¥185.74bn | ¥77.85bn | ¥124.70bn | ¥107.64bn | ¥94.65bn | ¥278.15bn | −¥116.19bn | ¥63.17bn |
| Net income | ¥141.68bn | ¥43.62bn | ¥100.32bn | ¥79.21bn | ¥68.42bn | ¥74.90bn | −¥97.66bn | ¥35.91bn |
| Diluted earnings per share | 78.88 | 24.28 | 55.82 | 44.07 | 38.07 | 41.67 | -54.57 | 20.06 |
| Cash from operations | ¥87.63bn | ¥205.13bn | ¥74.17bn | ¥229.49bn | ¥55.85bn | ¥102.85bn | ¥17.23bn | ¥67.29bn |
| Capital spending | −¥12.62bn | −¥16.60bn | −¥16.80bn | −¥13.44bn | −¥12.81bn | −¥9.70bn | −¥2.29bn | −¥15.60bn |
| Free cash flow | ¥75.01bn | ¥188.53bn | ¥57.38bn | ¥216.06bn | ¥43.04bn | ¥93.15bn | ¥14.94bn | ¥51.69bn |
| Total assets | ¥3.69trn | ¥3.57trn | ¥3.60trn | ¥3.45trn | ¥3.34trn | ¥3.34trn | ¥3.45trn | ¥3.46trn |
| Cash and short-term investments | ¥244.70bn | ¥281.61bn | ¥254.30bn | ¥287.05bn | ¥215.40bn | ¥188.37bn | ¥179.87bn | ¥292.99bn |
| Debt | ¥269.87bn | ¥565.95bn | ¥405.27bn | ¥420.54bn | ¥331.41bn | ¥847.76bn | ¥329.85bn | ¥927.50bn |
| Shareholders' equity | ¥1.94trn | ¥1.83trn | ¥1.76trn | ¥1.61trn | ¥1.48trn | ¥1.51trn | ¥1.49trn | ¥1.53trn |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 12.1% | 11.4% | 4.5% |
| Operating income | 13.7% | 10.8% | 4.6% |
| Net income | 43.5% | 19.3% | 4.2% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 77.9% | 79.4% | 79.7% | 78.6% |
| Operating margin | 16.9% | 15.2% | 16.1% | 18.0% |
| Net margin | 8.4% | 6.4% | 7.2% | 10.4% |
Valuation history
At each fiscal year end
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 15.4 | 74.1 | 161.1 | 30.8 | 29.5 | 28.8 | 15.2 | 15.8 | 16.4 | 13.3 |
| Price to sales | 2.1 | 2.0 | 1.7 | 2.0 | 2.8 | 2.8 | 2.3 | 2.7 | 2.1 | 2.2 |
Dividends and splits
Per share, in the currency the company pays
Paid for 36 years. Last went ex-dividend on 29 Sept 2026.
| FY2027 | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 40.00 | 115.00 | 72.00 | 65.00 | 55.00 | 46.00 | 41.00 | 39.00 |
- 5-for-1 split · 27 Mar 2014
- 11-for-10 split · 26 Mar 1991
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.